Press Release
December 14, 2022

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

The Life Sciences team advised Wave Life Sciences (Nasdaq: WVE) on its strategic collaboration with GSK (LSE/NYSE: GSK) to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006. The discovery collaboration has an initial four-year research term. It combines GSK’s unique insights from human genetics, as well as its global development and commercial capabilities, with Wave’s proprietary discovery and drug development platform, PRISM™.

Pursuant to the collaboration agreement, Wave will receive an upfront payment of $170 million, which includes a cash payment of $120 million and a $50 million equity investment, when the collaboration agreement takes effect. Wave will also receive research support funding in respect of its target validation activities under the collaboration. In addition, assuming WVE-006 and GSK’s eight collaboration programs achieve initiation, development, launch, and commercialization milestones, Wave would be eligible to receive up to $3.3 billion in cash milestone payments.

Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

The Goodwin team was led by Sarah Solomon, Gregg Katz, Jennifer Ford, and Paul Jin.

For more details, read the press release and articles in Endpoints News and Fierce Biotech.